Drug, across the briefings
Copanlisib across 18 cancers
Copanlisib appears in 18 of the briefings; no FDA label names any of them.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Anal cancer | approved on PIK3CA | — | — | |
| Bladder cancer | approved on PIK3CA | 3 | 1 | |
| Breast cancer | approved on PIK3CA | 11 | 3 | |
| Cervical cancer | approved on PIK3CA | 1 | 1 | |
| Chronic lymphocytic leukemia | approved on PIK3CD | 4 | 1 | |
| Colorectal cancer | approved on PIK3CA | 2 | 1 | |
| Endometrial cancer | approved on PIK3CA | 5 | 1 | |
| Follicular lymphoma | approved on PIK3CD | 6 | 2 | |
| Gallbladder cancer | approved on PIK3CA | 1 | 0 | |
| Gastric cancer | approved on PIK3CA | 1 | 1 | |
| Glioblastoma | approved on PIK3CA | — | — | |
| Head and neck cancer | approved on PIK3CA | 2 | 1 | |
| Lower-grade glioma | approved on PIK3CA | — | — | |
| Merkel cell carcinoma | approved on PIK3CA | — | — | |
| Nasopharyngeal carcinoma | approved on PIK3CA | — | — | |
| Ovarian cancer | approved on PIK3CA | 4 | 1 | |
| Thyroid cancer | approved on PIK3CA | 1 | 0 | |
| Vulvar cancer | approved on PIK3CA | — | — |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.